Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.47 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2076075 | 0.98 | AOC3 (0.56) | AOC3SMN1; SMN2POLBCYP1A2CHRM2 | |
| SCHEMBL1253168 | 0.83 | AOC3 (0.64) | AOC3SMN1; SMN2POLBCYP1A2KDM4E | |
| SCHEMBL8910900 | 0.82 | AOC3 (0.56) | AOC3SMN1; SMN2POLBCYP1A2CHRM2 | |
| SCHEMBL4945959 | 0.82 | KDM1A (0.46) | AOC3SMN1; SMN2POLBCYP1A2CHRM2 | |
| Hydrochloric Acid SCHEMBL7084948 | 0.82 | AOC3 (0.45) | AOC3SMN1; SMN2POLBCYP1A2CHRM2 | |
| Hydrochloric Acid SCHEMBL7366474 | 0.82 | AOC3 (0.62) | AOC3CYP1A2KDM4EAPOBEC3ACTDSP1 | |
| SCHEMBL622628 | 0.81 | CA12 (0.53) | SMN1; SMN2POLBCYP1A2KDM4ETSHR | |
| SCHEMBL30883 | 0.80 | AOC3 (0.55) | AOC3SMN1; SMN2POLBCYP1A2CHRM2 | |
| SCHEMBL8597522 | 0.79 | IDO1 (0.55) | AOC3SMN1; SMN2POLBCYP1A2CHRM2 | |
| Hydrochloric Acid SCHEMBL5485820 | 0.79 | CA12 (0.51) | SMN1; SMN2POLBCYP1A2KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6444662-B1 | REACTION WITH AMINE BASE | WILLMAR SCHWABE GMBH & CO. (DE) | 2002-09-03 | — | — | US | claimed |
| CN-114306613-A | Pharmaceutical composition | 查尔斯顿实验室公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-106957314-B | Pyrimidine derivatives as RAF kinase inhibitors | 苏尼西斯制药有限公司 | 2019-12-31 | — | — | CN | disclosed |
| EP-3231798-B1 | THIAZOLE INTERMEDIATES USEFUL IN THE PREPARATION OF RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS INC (US) | 2019-10-09 | — | — | EP | disclosed |
| WO-2019152685-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND METHODS OF USING SAME | APTINYX INC. (US) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019152685-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND METHODS OF USING SAME | APTINYX INC. (US) | 2019-08-08 | — | — | WO | disclosed |
| US-20180099956-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | MITHRIDION, INC. | 2018-04-12 | — | — | US | disclosed |
| US-9920048-B2 | Substituted pyrimidines for inhibiting Raf kinase activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| EP-3231798-A1 | THIAZOLE INTERMEDIATES USEFUL IN THE PREPARATION OF RAF KINASE INHIBITORS | Sunesis Pharmaceuticals, Inc. (US) | 2017-10-18 | — | — | EP | disclosed |
| US-9738633-B2 | Cognition enhancing compounds and compositions, methods of making, and methods of treating | NEUROSOLIS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| EP-1326849-A1 | BENZODIAZEPINE DERIVATIVES AS INHIBITORS OF GAMMA SECRETASE | Merck Sharp & Dohme Limited (GB) | 2003-07-16 | — | — | EP | disclosed |
| EP-1294702-A1 | BENZODIAZEPINE DERIVATIVES AS APP MODULATORS | MERCK SHARP & DOHME LTD. (GB) | 2003-03-26 | — | — | EP | disclosed |
| EP-1290012-A2 | 2-AMINO-3-HYDROXY-4-TERT-LEUCYL-AMINO-5-PHENYL-PENTANOIC ACID AMIDE DERIVATIVES | Novartis AG (CH) | 2003-03-12 | — | — | EP | disclosed |
| WO-2002030912-A1 | BENZODIAZEPINE DERIVATIVES AS INHIBITORS OF GAMMA SECRETASE | MERCK SHARP & DOHME LIMITED (GB) | 2002-04-18 | — | — | WO | disclosed |
| WO-2001090084-A1 | BENZODIAZEPINE DERIVATIVES AS APP MODULATORS | MERCK SHARP & DOHME LIMITED (GB) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001089282-A2 | 2-AMINO-3-HYDROXY-4-TERT-LEUCYL-AMINO-5-PHENYL-PENTANOIC ACID AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2001-11-29 | — | — | WO | disclosed |
| EP-1091928-A1 | NOVEL ACYL PSEUDODIPEPTIDES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | OM Pharma (CH) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000000462-A1 | NOVEL ACYL PSEUDODIPEPTIDES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | OM PHARMA (CH) | 2000-01-06 | — | — | WO | disclosed |
| EP-0801083-A2 | Improved functionalized resin for chemical synthesis | PFIZER INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| US-4497815-A | 1-(N-Substituted carbamoyl)-5-fluorouracil derivatives and the carcinostatic agents containing same as active ingredients | Ozaki, Shoichiro (JP) | 1985-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099956-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | CHRM3, CHRM4, CHRM5 | AOC3 405/4885SMN1; SMN2 1001/4885POLB 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.